104997-09-3

Basic information

• Product Name: N-(3-aminophenyl)benzenesulfonamide
• Synonyms: N-(3-aminophenyl)benzenesulfonamide;Benzenesulfonamide, N-(3-aminophenyl)-
• CAS NO: 104997-09-3
• Molecular Formula: C₁₂H₁₂N₂O₂S
• Molecular Weight: 248.30088
• Mol File: 104997-09-3.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(3-aminophenyl)benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-aminophenyl)benzenesulfonamide(104997-09-3)
• EPA Substance Registry System: N-(3-aminophenyl)benzenesulfonamide(104997-09-3)

Safety Data

• Hazardous Substances Data: 104997-09-3(Hazardous Substances Data)

Upstream product

• 108-45-2 m-phenylenediamine 
• 98-09-9 benzenesulfonyl chloride 
• 99-09-2 3-nitro-aniline 
• 98-80-6 phenylboronic acid 
• 98-10-2 benzenesulfonamide 
• 591-19-5 m-Bromoaniline 
• 80-37-5 N-(3-nitrophenyl)benzenesulfonamide 

Downstream Products

• 1426921-94-9 {[N-(3-aminophenyl)benzenesulfonamide](p-cymene)dichlororuthenium(II)} 
• 1616385-58-0 N-[2-[3-(benzenesulfonamido)anilino]pyrimidin-5-yl]-3,4-dimethyl-1H-pyrazole-5-carboxamide 
• 372093-72-6 N-(3-Benzensulfonylaminophenyl)-(2-chloro-5-nitrophenyl)carboxamide 

Relevant articles and documents

Sequential C-S and S-N Coupling Approach to Sulfonamides

A one-pot three-component reaction involving nitroarenes, (hetero)arylboronic acids, and potassium pyrosulfite leading to sulfonamides was described. A broad range of sulfonamides bearing different reactive functional groups were obtained in good to excellent yields through sequential C-S and S-N coupling that does not require metal catalysts.

Sulfonamide urease inhibiting agent and preparation method and application thereof

Benzene sulfonamide compounds have a structural formula as shown in the specification, have great inhibiting effects on urease and can be used for preparation of medicines for treating gastritis, gastric ulcer, lithangiuria and the like. The invention fur

Potent Pan-Raf and Receptor Tyrosine Kinase Inhibitors Based on a Cyclopropyl Formamide Fragment Overcome Resistance

While selective BRafV600E inhibitors have been proven effective clinically, acquired resistance rapidly develops through reactivation of the mitogen-activated protein kinase (MAPK) pathway. Simultaneous targeting of multiple nodes in the pathway offers the prospect of enhanced efficacy as well as reduced potential for acquired resistance. Replacement pyridine group of Y-1 by a cyclopropyl formamide group afforded I-01 as a novel multitargeted kinase inhibitor template. I-01 displayed enzyme potency against Pan-Raf and receptor tyrosine kinases (RTKs). Based on the binding mode of I-01, analogues I-02-I-18 were designed and synthesized. The most promising compound I-16 potently inhibits all subtypes of Rafs with IC50 values of 3.49 (BRafV600E), 8.86 (ARaf), 5.78 (BRafWT), and 1.65 nM (CRaf), respectively. I-16 not only exhibit comparable antiproliferative activities with positive control compounds against HepG2, SW579, MV4-11, and COLO205 cell lines, but also suppress the proliferation of melanoma SK-MEL-2 harboring overexpressed BRafWT with IC50 values of 0.93 μM. The Western blot results for the ERK inhibition in human melanoma SK-MEL-2 cell lines show that I-16 inhibits the proliferation of SK-MEL-2 cell lines without paradoxical activation of ERK, which support the hypothesis that the inhibition of Pan-Raf and RTKs might be a tractable strategy to overcome the resistance of melanoma induced by the therapy with the current selective BRafV600E inhibitors.